Project Highlights

RBCC Forms Joint Venture With Cutting-Edge Drug Delivery Company TheraKine

As part of a bold expansion into the $60 billion global drug delivery market, Rainbow BioSciences, the biotech division of Rainbow Coral Corp. (RBCC), today announced it has formed a new partnership to solve the problems posed by systemic drug delivery.

RBCC signed a joint venture agreement with TheraKine Ltd., the developer of a revolutionary, sustained-release drug delivery platform that could soon make local delivery of biologic agents and small molecules safer, more effective and more convenient than ever before. The company has developed and patented these novel, tunable technologies with the potential to enable selective, site-specific drug delivery, allowing for lower drug concentrations and significantly reducing the risk of drug toxicity.

Newsfeed